Clinical and Biomarker Characteristics According to Clinical Spectrum of Alzheimer’s Disease (AD) in the Validation Cohort of Korean Brain Aging Study for the Early Diagnosis and Prediction of AD

Journal of Clinical Medicine

Seong Hye Choi¹  Jinwoo Hong²  Jong-Min Lee²  Gilsoon Park²  Yong-Ho Choi²  Hyuntae Park³  Kyung Won Park⁴  Soo Jin Yoon⁵  Jee Hyang Jeong⁶  Jae-Won Jang⁷  Jihye Hwang⁸  Bora Yoon⁹  Eun-Joo Kim^1,10  Hee Jin Kim^1,11  Jin Yong Hong^1,12  Dong Young Lee^1,13  Yu Kyeong Kim^1,14  Ju-Hee Kang^1,15  Dahyun Yi^1,16  Min Soo Byun^1,16 

[1] Department of Seoul National University College of Medicine, Seoul 03080, Korea;Department of Biomedical Engineering, Hanyang University, Seoul 04763, Korea;Department of Health Care and Science, Dong-A University, Busan 49315, Korea;Department of Neurology, Dong-A Medical Center, Dong-A University College of Medicine, Busan 49201, Korea;Department of Neurology, Eulji University School of Medicine, Daejeon 35233, Korea;Department of Neurology, Ewha Womans University School of Medicine, Seoul 07985, Korea;Department of Neurology, Kangwon National University Hospital, Kangwon National University College of Medicine, Chuncheon 24289, Korea;Department of Neurology, Keimyung University Dongsan Medical Center, Daegu 41931, Korea;Department of Neurology, Konyang University College of Medicine, Daejeon 35365, Korea;Department of Neurology, Pusan National University Hospital, Pusan National University School of Medicine and Medical Research Institute, Busan 49241, Korea;Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea;Department of Neurology, Yonsei University Wonju College of Medicine, Wonju 26426, Korea;;Department of Neuropsychiatry, Seoul National University Hospital &Department of Nuclear Medicine, SMG-SNU Boramae Medical Center, Seoul 07061, Korea;Department of Pharmacology, Inha University School of Medicine, Incheon 22212, Korea;Institute of Human Behavioral Medicine, Medical Research Center Seoul National University, Seoul 03080, Korea;

关键词: Alzheimer’s disease;    mild cognitive impairment;    biomarkers;    cohort study;    subjective cognitive decline;   

DOI  :  10.3390/jcm8030341

来源: DOAJ

【 摘 要 】

We aimed to present the study design of an independent validation cohort from the Korean Brain Aging Study for the Early Diagnosis and Prediction of Alzheimer’s disease (AD) (KBASE-V) and to investigate the baseline characteristics of the participants according to the AD clinical spectrum. We recruited 71 cognitively normal (CN) participants, 96 with subjective cognitive decline (SCD), 72 with mild cognitive impairment (MCI), and 56 with AD dementia (ADD). The participants are followed for three years. The Consortium to Establish a Registry for AD scores was significantly different between all of the groups. The logical memory delayed recall scores were significantly different between all groups, except between the MCI and ADD groups. The Mini-Mental State Examination score, hippocampal volume, and cerebrospinal fluid (CSF) amyloid-β42 level were significant difference among the SCD, MCI, and ADD groups. The frequencies of participants with amyloid pathology according to PET or CSF studies were 8.9%, 25.6%, 48.3%, and 90.0% in the CN, SCD, MCI, and ADD groups, respectively. According to ATN classification, A+/T+/N+ or A+/T+/N− was observed in 0%, 15.5%, 31.0%, and 78.3% in the CN, SCD, MCI, and ADD groups, respectively. The KBASE-V showed a clear difference according to the AD clinical spectrum in neuropsychological tests and AD biomarkers.

【 授权许可】

Unknown